Quemliclustat

DB19160InvestigationalSmall molecule

Quemliclustat is under investigation in clinical trial NCT05329766 (A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies).

Formula / weight: C₂₀H₂₄ClFN₄O₉P₂ · 580.83 g/mol (avg)
Also known as: 1h-pyrazolo(3,4-b)pyridin-4-amine, 6-chloro-n-((1s)-1-(2-fluorophenyl)ethyl)-1-(5-o-(hydroxy(phosphonomethyl)phosphinyl)-.beta.-d-ribofuranosyl)- · 2-chloro-n6 -((1s)-1-(2-fluorophenyl)ethyl)-8-aza-1,7- dicarbaadenosine 5'-(trihydrogen 2-carbadiphosphate)
Code names: AB-680

Resolves to

Compound

UNIIJ6K8WSV73ACAS2105904-82-1ChEMBLCHEMBL4471306

Structure

InChIKeyMFYLCAMJNGIULC-KCVUFLITSA-NSMILESC[C@H](NC1=C2C=NN([C@@H]3O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(Cl)=C1)C1=CC=CC=C1F

Targets

P21589NT5E

What you can answer from here — as of September 24, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Quemliclustat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account